Avant Brands Inkomsten in het verleden
Verleden criteriumcontroles 0/6
Avant Brands's earnings have been declining at an average annual rate of -0.7%, while the Pharmaceuticals industry saw earnings growing at 13.1% annually. Revenues have been growing at an average rate of 41% per year.
Belangrijke informatie
-0.7%
Groei van de winst
21.5%
Groei van de winst per aandeel
| Pharmaceuticals Groei van de industrie | 7.3% |
| Inkomstengroei | 41.0% |
| Rendement op eigen vermogen | -32.8% |
| Nettomarge | -51.0% |
| Laatste winstupdate | 31 Aug 2024 |
Recente prestatie-updates uit het verleden
Recent updates
Opbrengsten en kosten
Hoe Avant Brands geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.
Inkomsten en omzetgeschiedenis
| Datum | Inkomsten | Inkomsten | G+A Uitgaven | R&D-uitgaven |
|---|---|---|---|---|
| 31 Aug 24 | 30 | -15 | 12 | 0 |
| 31 May 24 | 28 | -11 | 12 | 0 |
| 29 Feb 24 | 27 | -8 | 11 | 0 |
| 30 Nov 23 | 26 | -5 | 12 | 0 |
| 31 Aug 23 | 29 | -4 | 11 | 0 |
| 31 May 23 | 27 | -3 | 9 | 0 |
| 28 Feb 23 | 23 | -7 | 12 | 0 |
| 30 Nov 22 | 20 | -8 | 11 | 0 |
| 31 Aug 22 | 15 | -10 | 11 | 0 |
| 31 May 22 | 13 | -14 | 10 | 0 |
| 28 Feb 22 | 12 | -12 | 7 | 0 |
| 30 Nov 21 | 9 | -11 | 6 | 0 |
| 31 Aug 21 | 9 | -11 | 5 | 0 |
| 31 May 21 | 9 | -9 | 5 | 0 |
| 28 Feb 21 | 8 | -8 | 5 | 0 |
| 30 Nov 20 | 8 | -10 | 5 | 0 |
| 31 Aug 20 | 7 | -4 | 5 | 0 |
| 31 May 20 | 6 | -6 | 6 | 0 |
| 29 Feb 20 | 5 | -8 | 7 | 0 |
| 30 Nov 19 | 2 | -10 | 9 | 0 |
| 31 Aug 19 | 1 | -11 | 10 | 0 |
| 31 May 19 | 0 | -11 | 11 | 0 |
| 28 Feb 19 | 0 | -10 | 10 | 0 |
| 30 Nov 18 | 0 | -11 | 10 | 0 |
Kwaliteitswinsten: 1BU is currently unprofitable.
Groeiende winstmarge: 1BU is currently unprofitable.
Analyse vrije kasstroom versus winst
Analyse van de winstgroei in het verleden
Winsttrend: 1BU is unprofitable, and losses have increased over the past 5 years at a rate of 0.7% per year.
Versnelling van de groei: Unable to compare 1BU's earnings growth over the past year to its 5-year average as it is currently unprofitable
Winst versus industrie: 1BU is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (28.7%).
Rendement op eigen vermogen
Hoge ROE: 1BU has a negative Return on Equity (-32.84%), as it is currently unprofitable.